Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04887857 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
10
Study locations

NCT04887857: Completed Phase 1 study of Leukemia, Myeloid, Acute, sponsored by Celgene.

NCT04887857 is a Phase 1 study of Leukemia, Myeloid, Acute that has completed, run by Celgene. The registered enrollment target is 6 participants, below the 116-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (95% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04887857, a Phase 1 study of Leukemia, Myeloid, Acute, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.

Conditions Studied

Leukemia, Myeloid, Acute

Interventions

  • DRUG Venetoclax
  • DRUG CC-486

Study Locations (10)

New York

  • Local Institution - 106 - New York
  • Local Institution - 113 - New York

California

  • Local Institution - 104 - Stanford

Colorado

  • Local Institution - 110 - Denver

Massachusetts

  • Local Institution - 105 - Boston

Ohio

  • Local Institution - 102 - Cleveland

Oklahoma

  • Local Institution - 111 - Oklahoma City

Texas

  • Local Institution - 101 - Houston

Victoria

  • Local Institution - 202 - North Melbourne

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2021-12-01
Est. Completion 2024-01-08
Phase Phase 1
Celgene

308 total trials

What the finished NCT04887857 record still lists

NCT04887857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 116-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT04887857 lists 10 locations in 9 states (New York, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT04887857 about?

NCT04887857 is a clinical study titled "A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.

What is the current status of trial NCT04887857?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-12-01. Estimated completion is 2024-01-08.

What conditions does trial NCT04887857 study?

This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.

What interventions are being tested in trial NCT04887857?

The interventions under investigation include: Venetoclax (DRUG), CC-486 (DRUG).

Who is sponsoring clinical trial NCT04887857?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04887857 being conducted?

This trial has 10 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia, Myeloid, Acute

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04887857's enrollment target sits among peer trials

6 31st of 30 the lowest of 30 other Leukemia, Myeloid, Acute trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia, Myeloid, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04887857, the US trial registry maintained by the National Library of Medicine. NCT04887857 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.